Neil Wilkie
CEO
Mironid
Mironid is developing small-molecule therapeutics that target cAMP degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases. The company aims to address the significant unmet medical needs in the treatment landscape for these degenerative conditions.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$38.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases have limited effective treatment options, resulting in significant unmet medical needs for patients suffering from these degenerative conditions. Current therapies do not directly target the central signaling mechanisms driving disease progression.
Solution
Mironid is developing a pipeline of novel small-molecule therapeutics designed to directly target cAMP-degrading phosphodiesterase (PDE) enzymes, which play a central role in the signaling pathways implicated in ADPKD. By selectively modulating PDE activity, Mironid's therapies aim to address the underlying mechanisms driving cyst growth and kidney dysfunction in ADPKD and other rare kidney diseases. The company's approach seeks to provide differentiated therapies with the potential to transform the treatment landscape and improve outcomes for patients with these conditions. Mironid is focused on progressing its drug development programs to generate innovative treatments that address the high unmet medical need in this patient population.
Target Audience
The primary target audience includes patients diagnosed with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases, as well as the healthcare professionals (nephrologists) who treat them.
Features
- Small-molecule therapeutics targeting cAMP-degrading phosphodiesterase enzymes.
- Focus on allosteric modulation of long-form PDE4 enzymes.
- Pipeline of drug development programs targeting the central signaling mechanism in ADPKD.
- Development of novel and differentiated therapies for rare kidney diseases.